Education
About Us
Working with TipRanks
Follow Us
Outlook Therapeutics (OTLK)
NASDAQ:OTLK
OTLK Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.87 - $12.85
Previous CloseN/A
Volume358.39K
Average Volume (3M)451.69K
Market Cap
$47.71M
Enterprise Value$142.47M
Total Cash (Recent Filing)$43.63M
Total Debt (Recent Filing)$31.84M
Price to Earnings (P/E)―
Beta-0.76
Next Earnings
May 14, 2025EPS Estimate
-0.54Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-7.94
Shares Outstanding32,017,178
10 Day Avg. Volume304,025
30 Day Avg. Volume451,688
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-1.10
P/FCF Ratio0.00
Enterprise Value/Market Cap2.99
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda14.74
Forecast
1Y Price Target
$10.00Price Target Upside562.25% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
---
Outlook Therapeutics News
PremiumCompany Announcements
Outlook Therapeutics Issues Convertible Note to Avondale
---
Bulls Say, Bears Say
Bulls Say
Financial ValuationThe current valuation is seen as attractive, representing significant upside potential if the FDA approves ONS-5010.
Market PotentialOutlook could disrupt over half the ocular anti-VEGF injection market by volume with what could emerge as the first FDA-approved intravitreal formulation of bevacizumab.
Regulatory ProgressThe FDA agreed to the Special Protocol Assessment for additional trials, indicating a path forward for BLA approval.
Bears Say
Development Program RiskONS-5010 is the company's sole active development program.
Regulatory ChallengesONS-5010 missed the primary endpoint of non-inferiority at week 8 set forth in the special protocol assessment with the FDA.
Uncertainty In FDA EvaluationIt's not clear how the FDA is going to recognize the non-inferiority margin at week 12, which was not a pre-specified endpoint and there was no alignment before readout, so the agency will view this as an 'exploratory' endpoint.
---
Ownership Overview
27.93% Insiders
4.05% Mutual Funds
1.35% Other Institutional Investors
62.10% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
OTLK FAQ
What was Outlook Therapeutics’s price range in the past 12 months?
Outlook Therapeutics lowest stock price was $0.87 and its highest was $12.85 in the past 12 months.
What is Outlook Therapeutics’s market cap?
Outlook Therapeutics’s market cap is $47.71M.
When is Outlook Therapeutics’s upcoming earnings report date?
Outlook Therapeutics’s upcoming earnings report date is May 14, 2025 which is in 53 days.
How were Outlook Therapeutics’s earnings last quarter?
Outlook Therapeutics released its earnings results on Feb 14, 2025. The company reported -$0.89 earnings per share for the quarter, missing the consensus estimate of -$0.76 by -$0.13.
Is Outlook Therapeutics overvalued?
According to Wall Street analysts Outlook Therapeutics’s price is currently Undervalued.
Does Outlook Therapeutics pay dividends?
Outlook Therapeutics does not currently pay dividends.
What is Outlook Therapeutics’s EPS estimate?
Outlook Therapeutics’s EPS estimate is -0.54.
How many shares outstanding does Outlook Therapeutics have?
Outlook Therapeutics has 32,017,178 shares outstanding.
What happened to Outlook Therapeutics’s price movement after its last earnings report?
Outlook Therapeutics reported an EPS of -$0.89 in its last earnings report, missing expectations of -$0.76. Following the earnings report the stock price went up 1.63%.
Which hedge fund is a major shareholder of Outlook Therapeutics?
Currently, no hedge funds are holding shares in OTLK
---
Outlook Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$10.00 (562.25% Upside)
$10.00 (562.25% Upside)
Blogger Sentiment
Bullish
OTLK Sentiment 100%
Sector Average 70%
Sector Average 70%
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.4%
Last 30 Days ▼ 5.1%
Last 30 Days ▼ 5.1%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-78.55%
12-Months-Change
Fundamentals
Return on Equity
<0.01%
Trailing 12-Months
Asset Growth
-21.58%
Trailing 12-Months
Company Description
Outlook Therapeutics
Outlook Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The firm engages in the identification, development, manufacture, and commercialization of complex biosimilar therapeutics. It focuses on monoclonal antibodies, in the disease areas of immunology and oncology. The company was founded by Pankaj Mohan on January 5, 2010 and is headquartered in Cranbury, NJ.
---
OTLK Stock 12 Month Forecast
Average Price Target
$10.00
▲(562.25% Upside)
Technical Analysis
Best Analysts Covering OTLK
1 Year
1 Year Success Rate
1/20 ratings generated profit
1 Year Average Return
-49.85%
reiterated a buy rating last month
Copying Douglas Tsao's trades and holding each position for 1 Year would result in 5.00% of your transactions generating a profit, with an average return of -49.85% per trade.
---